14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
OKUR vs OBIO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Orchestra BioMed Holdings, Inc. (OBIO) captures the overall head-to-head institutional edge over OnKure Therapeutics, Inc. (OKUR) on higher Unified Composite conviction (41.1/100 SELL vs. 36.0/100 SELL) after splitting the core matrix 4–4 (led by Valuation Multiples, Growth & Scale), while OKUR wins 3–2 across the 6-pillar growth and valuation breakdown. OKUR trades at $2.70 (N/M Forward P/E, 0.0% operating margin) versus OBIO at $6.58 (N/M Forward P/E, -195.4% operating margin).
Growth vs. Quality Trade-Off: OBIO earns the overall head-to-head edge with a stronger Unified Composite Score (41.1/100 SELL vs. OKUR 36.0/100 SELL) and 1.18β · 88% Vol risk profile, whereas OKUR leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although OBIO compares more favorably head-to-head, both OKUR (36.0/100 SELL) and OBIO (41.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: OKUR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7); meanwhile OBIO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OKUR vs OBIO. Trailing 12-month operating profitability (OKUR 0.0% vs OBIO -195.4%) and valuation multiples (OKUR N/M vs OBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $550.9M market capitalization and -195.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ OKUR vs OBIO Key Questions & Quantitative Answers
As of Nov 20, 2026, Orchestra BioMed Holdings, Inc. (OBIO) captures the overall head-to-head institutional edge over OnKure Therapeutics, Inc. (OKUR) on higher Unified Composite conviction (41.1/100 SELL vs. 36.0/100 SELL) after splitting the core matrix 4–4 (led by Valuation Multiples, Growth & Scale), while OKUR wins 3–2 across the 6-pillar growth and valuation breakdown. OKUR trades at $2.70 (N/M Forward P/E, 0.0% operating margin) versus OBIO at $6.58 (N/M Forward P/E, -195.4% operating margin). Growth vs. Quality Trade-Off: OBIO earns the overall head-to-head edge with a stronger Unified Composite Score (41.1/100 SELL vs. OKUR 36.0/100 SELL) and 1.18β · 88% Vol risk profile, whereas OKUR leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although OBIO compares more favorably head-to-head, both OKUR (36.0/100 SELL) and OBIO (41.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: OKUR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7); meanwhile OBIO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
OBIO leads the Growth & Scale pillar: OKUR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with OBIO at -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin). On trailing 12-month operating scale, OKUR generates N/A in USD-normalized revenue versus $31M for OBIO. In operating R&D and SG&A reinvestment, OKUR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OBIO.
OBIO screens cheaper on headline valuation multiples. OKUR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OKUR (-55.2% ROE) versus OBIO (-182.3% ROE) capital efficiency.
In options market volatility and institutional positioning, OKUR carries 89.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.96β · 100% Vol realized risk). By comparison, OBIO carries 78.2% implied volatility (21st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.18β · 88% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.